Bioequivalence Study of Ezetimibe/Atorvastatin Formulations in Healthy Volunteers

The primary objective of this study is to evaluate the **bioequivalence** of two formulations of **ezetimibe/atorvastatin** in healthy volunteers. Bioequivalence studies are crucial in determining whether different formulations of a drug release the active ingredient into the bloodstream at the same rate and extent, ensuring therapeutic equivalence. This is clinically relevant as it ensures that patients receive the same therapeutic benefits and safety profile from different formulations of the same medication.

The clinical trial involves **healthy volunteers** as the study population, encompassing both male and female participants. The age range of the participants is categorized as adults, although specific age details are not provided. The trial includes a vulnerable population, indicating that special considerations may be necessary for certain participants. The sponsor has not provided information regarding the total number of participants involved in the study. Selection criteria and lifestyle considerations such as diet, physical activity, or habits have not been disclosed. The trial population was selected to include a diverse group, but specific inclusion or exclusion criteria have not been detailed by the sponsor.

The clinical trial is designed to evaluate the **bioequivalence** of two formulations of ezetimibe/atorvastatin in **healthy volunteers**. This study is a Phase 2, randomized, double-blind, controlled trial. The trial is expected to commence recruitment on August 30, 2023, and is estimated to conclude by November 20, 2023. The trial involves a sequence of study visits, beginning with an inclusion visit, where participants will undergo screening to determine eligibility based on predefined criteria. Following successful inclusion, participants will be randomly assigned to receive one of the two formulations under investigation.

Throughout the trial, participants will attend scheduled follow-up visits to monitor their health status and assess the pharmacokinetic parameters of the formulations. These visits are crucial for ensuring participant safety and collecting data necessary for the trial's objectives. The end-of-study visit will mark the completion of the trial for each participant, during which final assessments will be conducted to gather comprehensive data on the formulations' bioequivalence.

The expected duration of participant involvement in the trial is approximately three months, from the initial screening to the end-of-study visit. Participants may be subject to early termination from the study if they experience adverse events, fail to comply with study procedures, or withdraw consent. The trial's design and procedures are structured to maintain scientific rigor and ensure the reliability of the results obtained.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the **experimental medication**, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available.

Due to the lack of specific data, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be detailed. The absence of this information precludes the provision of a comprehensive description of the treatments used in this clinical trial.

The clinical trial is designed to assess efficacy in a Phase 2 study. The trial is scheduled to commence recruitment on August 30, 2023, with an estimated end date of November 20, 2023. The efficacy assessment will be conducted through a series of planned evaluations, although specific parameters or endpoints for efficacy evaluation are not detailed in the available data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The methods and tools for measuring efficacy, as well as the specific timepoints for these assessments, are not specified in the provided information. The trial's focus on efficacy is aligned with the objectives typical of a Phase 2 study, which generally aims to evaluate the effectiveness of a treatment in a specific patient population. The trial's design and execution will adhere to rigorous standards to ensure the reliability and validity of the efficacy data collected.